Shuchi Nahar's Weekend Blog!

Scope for Medical Devices and Impact of Covid-19 Polymedicure Company Overview Twitter Handle: @shuchi_nahar   Brief details about Medical Devices Industry The global medical devices market reached a value of nearly $456.9 billion in 2019, having increased at a compound annual growth rate (CAGR) of 4.4% since 2015. The market is expected to decline from $456.9 billion in 2019 to $442.5 billion in 2020 at a rate of -3.2%. The decline is mainly due to lockdowns imposed by the governments across the world that hindered the supply chain in the medical devices manufacturing industry. However, there is an unprecedented increase in the manufacturing of the ventilators and it's expected to rise in demand for syringes as covid vaccines are claimed to treat COVID-19 patients. The market is then expected to recover and grow at a CAGR of 6.1% from 2021 and reach $603.5 billion in 2023. Drivers for Growth of Medical Technology Sector in India The Indian medical device industry continues its

The Stronger Conviction for CDMO's - Bright Future Ahead Twitter Handle: @shuchi_nahar 1) Laurus Labs –The Complete Turnaround Story Laurus Labs is a leading R&D driven pharmaceuticals company established in 2005 with its headquarters in Hyderabad. It is among the leaders in the manufacturing of Active Pharmaceutical Ingredients (APIs) for Antiretroviral (ARV) and Hepatitis C (Hep-C) formulations. Other major API segments include therapeutic areas such as Oncology, Cardiovascular, and Anti-Diabetes. From a one-product company in 2010 to an Active Pharmaceutical Ingredients (APIs) company thereafter, the company has now emerged as one of India’s leading manufacturers of generics APIs for various complex therapies. Revenue Comparison FY19 v/s FY20 Significant Growth in CDMO For Detailed Analysis of the above company - https://myweekendspot.blogspot.com/2020/09/laurus-labs-company-overview.html To continue reading this great compilation of CDMO Companies Click the Link :  https://

Advance Enzyme  Technologies Ltd  – Pioneers in Enzyme Biotechnology Twitter Handle: @shuchi_nahar Link: https://myweekendspot.blogspot.com/2020/12/what-are-enzyme-biotechnology-market.html Incorporated by second-generation enzymologists, the Rathi brothers in 1989, Advanced Enzyme Technologies (AET) is one of the largest research-driven Indian enzyme companies with a product basket of 400+ proprietary products developed from 68 indigenous enzymes and probiotics. Broadly, the business can be divided into three segments – 1) Human healthcare 2) Animal healthcare 3) Industrial processing. It manufactures enzymes by using natural resources such as plants, fungal, bacterial, and animal sources, using environment-friendly biotechnology processes. It offers these products to 700+ customers across 45 countries worldwide. Product Insights This classification provides break-up on the basis of the enzyme function. For example: 1) Proteases : They break down proteins (used in in

What are Enzyme Biotechnology, Market Size, and its Growth Drivers Twitter Handle: @shuchi_nahar Enzymes are proteins that catalyze chemical reactions and thus often replace chemicals in products and industrial productions. Biotechnology could be traced back to thousands of years ago when humans started to use yeasts to make liquor. This may be the first dawn of biotechnology in food production. Along with the development of natural and social sciences, nowadays, biotechnology carries more colorful meanings. Indian Enzyme Market The Indian enzyme market is yet to find its feet, as it is quite small when compared to the other sectors in the country. However, the growing awareness about the capabilities of enzymes and the subsequent benefits (both nutrition and cost-wise) will be important growth factors in the coming years.  The developments in pharmaceuticals and chemical sectors will provide much-needed boost to the enzyme market and it is expected that the demand for specialty

Granules India Ltd. - Huge Scope of Growth Ahead Twitter Handle: @shuchi_nahar Company Overview Founded in 1991, Granules India Limited is a large-scale vertically integrated Company manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD). The Company over the years has created a strong presence in ‘the first line of defence’ products such as Paracetamol, Ibuprofen, Metformin, Methocarbamol, and Guaifenesin. Till date, Granules has filed 45 ANDAs, received approval for 29 products (12 in FY20) and launched five in the US. EBITDA margins have seen improving from better product mix, operating efficiencies and higher capacity utilisations. Also, the margins are expected to further expand with the launch of own label products in the US, a new facility commenced at Vizag and using its own Metformin with new capacity commissioned. In FY20 it received approval for 12 ANDAs. It has a further 16 ANDAs (45 cumulative fi